Literature DB >> 32831897

Update on the management of uveitis in children: an overview for the clinician.

Lucas Kim1, Alexa Li2, Sheila Angeles-Han3, Steven Yeh2, Jessica Shantha2.   

Abstract

INTRODUCTION: Pediatric uveitis comprises a range of ocular inflammatory diseases that may lead to vision impairment, often due to ocular complications from the disease itself or side effects of therapies. The impact on vision, visual functioning, and vision-related quality-of-life over the lifetime horizon can be substantial, underscoring the importance of appropriate ophthalmic evaluation, diagnostic testing and treatment. This review focuses on the anatomic classification, laboratory diagnosis, associated systemic diseases, and management of pediatric uveitis. AREAS COVERED: A review of the literature was performed to synthesize our current understanding of the anatomic classification of pediatric uveitis, disease epidemiology, associated systemic diseases, and management principles. We also review important corticosteroid-sparing strategies including non-biologic and biologic agents such as the anti-tumor necrosis factor (TNF)-alpha family of medications, given their key role in the treatment of pediatric uveitis, particularly juvenile idiopathic arthritis (JIA). Recent advances in the assessment of vision-related quality-of-life using the Effects of Youngsters' Eyesight on Quality of Life (EYE-Q) instrument are discussed. EXPERT OPINION: Pediatric uveitis can lead to long-term vision impairment if not appropriately screened and treated. JIA is the most common systemic disease associated with uveitis, is typically asymptomatic, and thus requires rigorous screening to detect uveitis and avoid secondary ocular complications. While topical and systemic corticosteroids are useful for the acute treatment of uveitis, the disease chronicity of many pediatric uveitis syndromes including JIA, often warrants early escalation of therapy to immunosuppressive medications including methotrexate (MTX) and anti-TNF-alpha inhibitors. Future directions include an improved understanding of risk factors for uveitis and better metrics to evaluate the impact of disease on vision-related quality-of-life of pediatric uveitis patients.

Entities:  

Year:  2019        PMID: 32831897      PMCID: PMC7437956          DOI: 10.1080/17469899.2019.1663731

Source DB:  PubMed          Journal:  Expert Rev Ophthalmol        ISSN: 1746-9899


  79 in total

Review 1.  Current approach in diagnosis and management of anterior uveitis.

Authors:  Rupesh V Agrawal; Somasheila Murthy; Virender Sangwan; Jyotirmay Biswas
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

2.  Prospective Determination of the Incidence and Risk Factors of New-Onset Uveitis in Juvenile Idiopathic Arthritis: The Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort.

Authors:  Jennifer J Y Lee; Ciarán M Duffy; Jaime Guzman; Kiem Oen; Nick Barrowman; Alan M Rosenberg; Natalie J Shiff; Gilles Boire; Elizabeth Stringer; Lynn Spiegel; Kimberly A Morishita; Bianca Lang; Deepti Reddy; Adam M Huber; David A Cabral; Brian M Feldman; Rae S M Yeung; Lori B Tucker; Karen Watanabe Duffy
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-11       Impact factor: 4.794

3.  Sporadic Blau syndrome with a double CARD15 mutation. Report of a case with lifelong follow-up.

Authors:  Roberta Priori; Michele Bombardieri; Francesca Romana Spinelli; Françoise Merlin; Corinne Miceli-Richard; Maurizio La Cava; Antonio Sili Scavalli; Raffaele Guerrisi; Jean-Pierre Hugot; Guido Valesini
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2004-10       Impact factor: 0.670

4.  Prognosticators for visual outcome in sarcoid uveitis.

Authors:  M R Dana; J Merayo-Lloves; D A Schaumberg; C S Foster
Journal:  Ophthalmology       Date:  1996-11       Impact factor: 12.079

5.  Surgical outcomes in childhood uveitic glaucoma.

Authors:  Brenda L Bohnsack; Sharon F Freedman
Journal:  Am J Ophthalmol       Date:  2012-10-02       Impact factor: 5.258

6.  Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.

Authors:  Vanesa Calvo-Río; Montserrat Santos-Gómez; Inmaculada Calvo; M Isabel González-Fernández; Berta López-Montesinos; Marina Mesquida; Alfredo Adán; María Victoria Hernández; Olga Maíz; Antonio Atanes; Beatriz Bravo; Consuelo Modesto; Gisela Díaz-Cordovés; Natalia Palmou-Fontana; Javier Loricera; M C González-Vela; Rosalía Demetrio-Pablo; J L Hernández; Miguel A González-Gay; Ricardo Blanco
Journal:  Arthritis Rheumatol       Date:  2017-03       Impact factor: 10.995

Review 7.  Pediatric uveitis: new and future treatments.

Authors:  Preema J Mehta; Janet L Alexander; H Nida Sen
Journal:  Curr Opin Ophthalmol       Date:  2013-09       Impact factor: 3.761

8.  Epidemiology and course of disease in childhood uveitis.

Authors:  Janine A Smith; Friederike Mackensen; H Nida Sen; Julie F Leigh; Angela S Watkins; Dmitry Pyatetsky; Howard H Tessler; Robert B Nussenblatt; James T Rosenbaum; George F Reed; Susan Vitale; Justine R Smith; Debra A Goldstein
Journal:  Ophthalmology       Date:  2009-08       Impact factor: 12.079

Review 9.  Ocular manifestations in Blau syndrome associated with a CARD15/Nod2 mutation.

Authors:  Toru Kurokawa; Takanobu Kikuchi; Kouichi Ohta; Hiroki Imai; Nagahisa Yoshimura
Journal:  Ophthalmology       Date:  2003-10       Impact factor: 12.079

Review 10.  Pediatric uveitis: An update.

Authors:  Parthopratim Dutta Majumder; Jyotirmay Biswas
Journal:  Oman J Ophthalmol       Date:  2013-09
View more
  3 in total

1.  Impact of the COVID-19 pandemic on uveitis patient care.

Authors:  Alexander F Vu; Shilpa Kodati; Phoebe Lin; Bahram Bodaghi; Parisa Emami-Naeini
Journal:  Br J Ophthalmol       Date:  2022-01-24       Impact factor: 4.638

Review 2.  Pediatric uveitis: Role of the pediatrician.

Authors:  Abhay Shivpuri; Inga Turtsevich; Ameenat Lola Solebo; Sandrine Compeyrot-Lacassagne
Journal:  Front Pediatr       Date:  2022-08-01       Impact factor: 3.569

3.  Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis.

Authors:  Joanne Thomas; Sanjana Kuthyar; Jessica G Shantha; Sheila T Angeles-Han; Steven Yeh
Journal:  Ann Eye Sci       Date:  2021-06-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.